Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
Cancer risk assessments for inorganic arsenic have been based on human epidemiological data, assuming a linear dose response below the range of observation of tumors. Part of the reason for the continued use of the linear approach in arsenic risk assessments is the lack of an adequate biologically based dose response (BBDR) model that could provide a quantitative basis for an alternative nonlinear approach. This paper describes elements of an ongoing collaborative research effort between the CIIT Centers for Health Research, the U.S. Environmental Protection Agency, ENVIRON International, and EPRI to develop BBDR modeling approaches that could be used to inform a nonlinear cancer dose response assessment for inorganic arsenic. These efforts are focused on: (1) the refinement of physiologically based pharmacokinetic (PBPK) models of the kinetics of inorganic arsenic and its metabolites in the mouse and human; (2) the investigation of mathematical solutions for multi-stage cancer models involving multiple pathways of cell transformation; (3) the review and evaluation of the literature on the dose response for the genomic effects of arsenic; and (4) the collection of data on the dose response for genomic changes in the urinary bladder (a human target tissue for arsenic carcinogenesis) associated with in vivo drinking water exposures in the mouse as well as in vitro exposures of both mouse and human cells. An approach is proposed for conducting a biologically based margin of exposure risk assessment for inorganic arsenic using the in vitro dose response for the expression of genes associated with the obligatory precursor events for arsenic tumorigenesis.
Clewell
Harvey J
HJ
CIIT Centers for Health Research, Research Triangle Park, NC 27709, USA. hclewell@ciit.org
Thomas
Russell S
RS
Gentry
P Robinan
PR
Crump
Kenny S
KS
Kenyon
Elaina M
EM
El-Masri
Hisham A
HA
Yager
Janice W
JW
D000818:Animals; D001151:Arsenic / Q000493:pharmacokinetics / Q000633:toxicity*; D001152:Arsenicals / Q000378:metabolism; D002101:Cacodylic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D002273:Carcinogens / Q000633:toxicity*; D049109:Cell Proliferation / Q000187:drug effects; D004247:DNA / Q000187:drug effects / Q000235:genetics; D004260:DNA Repair / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D051379:Mice; D017711:Nonlinear Dynamics; D020411:Oligonucleotide Array Sequence Analysis; D018384:Oxidative Stress / Q000187:drug effects; D011042:Poisons / Q000493:pharmacokinetics / Q000633:toxicity*; D015398:Signal Transduction / Q000187:drug effects; D014018:Tissue Distribution; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced
D001152:Arsenicals; D002273:Carcinogens; D011042:Poisons; C472511:dimethylarsinous acid; D004247:DNA; D002101:Cacodylic Acid; C020300:monomethylarsonic acid; D001151:Arsenic